| Date | Time | Source | Headline | Symbol | Company |
| 07/28/2010 | 7:53AM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/28/2010 | 7:50AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/28/2010 | 7:30AM | Business Wire | Allos Therapeutics Reports Second Quarter 2010 Financial Results | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/28/2010 | 7:13AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/28/2010 | 7:00AM | Business Wire | Allos Therapeutics Announces Topline Results from Phase 2b Study of FOLOTYN in Patients with Advanced Non-Small Cell Lung Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/12/2010 | 9:00AM | Business Wire | Allos Therapeutics to Report Second Quarter 2010 Financial Results on July 28, 2010 | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/02/2010 | 5:15PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 07/02/2010 | 5:13PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/25/2010 | 9:15AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:55PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:52PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:51PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:49PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:48PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:46PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/24/2010 | 6:44PM | Edgar (US Regulatory) | Initial Statement of Beneficial Ownership (3) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/17/2010 | 9:00AM | Business Wire | Allos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Cutaneous T-Cell Lymphoma ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/11/2010 | 11:45AM | Business Wire | Allos Therapeutics’ FOLOTYN Shows Activity & Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refrac... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/05/2010 | 9:00AM | Business Wire | Allos Therapeutics Reports New Data Demonstrating that Responses to FOLOTYN are Correlated with Prolonged Survival in Patient... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/04/2010 | 9:00AM | Business Wire | Allos Therapeutics to Present at Four Upcoming Investor Conferences | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/03/2010 | 9:14AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 06/01/2010 | 9:00AM | Business Wire | Allos Therapeutics Announces FOLOTYN® Data Presentations at the American Society of Clinical Oncology & the Congress of the ... | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/20/2010 | 9:00AM | Business Wire | Allos Therapeutics to Present at the Citi Investment Research Global Health Care Conference | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/18/2010 | 9:10AM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/18/2010 | 8:52AM | Dow Jones News | Allos Gets Orphan-Drug Designation For Bladder Cancer Drug | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/18/2010 | 8:00AM | Business Wire | Allos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation for the Treatment of Bladder Cancer | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/12/2010 | 5:53PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/10/2010 | 3:42PM | Edgar (US Regulatory) | Amended Statement of Ownership (SC 13G/A) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/05/2010 | 4:10PM | Edgar (US Regulatory) | Quarterly Report (10-Q) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |
| 05/05/2010 | 4:05PM | Edgar (US Regulatory) | Current report filing (8-K) | NASDAQ:ALTH | Allos Therapeutics, Inc. (MM) |